Trial Profile
Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 May 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as per ClinicalTrials.gov record.
- 08 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.